A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 2, 2022

Primary Completion Date

January 17, 2026

Study Completion Date

December 12, 2026

Conditions
Chronic Kidney Disease (CKD)
Interventions
DRUG

Vonsetamig

Administered by intravenous (IV) infusion

Trial Locations (10)

10016

RECRUITING

New York University Langone Health, New York

19104

RECRUITING

Penn Transplant Institute, Philadelphia

20007

RECRUITING

Medstar Georgetown Transplant Institute - 2-PHC, Washington D.C.

21224

RECRUITING

John Hopkins Hospital, Baltimore

55455

RECRUITING

University of Minnesota, Minneapolis

60611

RECRUITING

Comprehensive Transplant Center, Chicago

90048

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

92868

RECRUITING

University of California Irvine, Orange

94143

RECRUITING

Connie Frank Transplant Center at UCSF, San Francisco

06520

RECRUITING

Yale University of Medicine, New Haven

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY